Alluvi tirzepatide is emerged as a promising therapeutic candidate for the management of metabolic conditions. This preclinical evaluation assessed the efficacy and tolerability of tirzepatide 40mg in in vivo models of type 2 diabetes. The experiments demonstrated that tirzepatide 40mg substantially improved glycemic control and reduced insulin sen